Credit Suisse’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$1.72M Sell
197,789
-5,414,324
-96% -$65.7M ﹤0.01% 1959
2023
Q4
$64.2M Buy
5,612,113
+1,110,544
+25% +$11M 0.06% 314
2023
Q3
$43.4M Sell
4,501,569
-1,298,944
-22% -$12.7M 0.04% 423
2023
Q2
$61.7M Buy
5,800,513
+628,844
+12% +$6.76M 0.06% 330
2023
Q1
$54.4M Sell
5,171,669
-29,034
-0.6% -$325K 0.05% 372
2022
Q4
$64.4M Buy
5,200,703
+557,798
+12% +$6.33M 0.07% 307
2022
Q3
$48.1M Buy
4,642,905
+221,377
+5% +$2.51M 0.05% 385
2022
Q2
$51M Sell
4,421,528
-43,520
-1% -$513K 0.05% 377
2022
Q1
$56.2M Sell
4,465,048
-161,535
-3% -$1.85M 0.05% 403
2021
Q4
$53.9M Sell
4,626,583
-24,308
-0.5% -$298K 0.03% 603
2021
Q3
$60.7M Buy
4,650,891
+594,844
+15% +$7.69M 0.03% 569
2021
Q2
$52.2M Buy
4,056,047
+348,217
+9% +$3.99M 0.03% 661
2021
Q1
$41.5M Sell
3,707,830
-123,521
-3% -$1.3M 0.02% 787
2020
Q4
$43.6M Buy
3,831,351
+172,393
+5% +$1.89M 0.02% 776
2020
Q3
$32.9M Sell
3,658,958
-42,731
-1% -$425K 0.02% 788
2020
Q2
$38.2M Buy
3,701,689
+275,931
+8% +$2.82M 0.03% 651
2020
Q1
$34.6M Buy
3,425,758
+362,615
+12% +$4.26M 0.03% 568
2019
Q4
$40.8M Sell
3,063,143
-243,779
-7% -$2.69M 0.03% 656
2019
Q3
$28.4M Buy
3,306,922
+1,385,005
+72% +$13.5M 0.02% 720
2019
Q2
$21M Buy
1,921,917
+14,857
+0.8% +$166K 0.02% 901
2019
Q1
$21.6M Buy
1,907,060
+7,644
+0.4% +$85.4K 0.02% 821
2018
Q4
$16.5M Buy
1,899,416
+253,291
+15% +$2.91M 0.02% 892
2018
Q3
$25.4M Buy
1,646,125
+76,552
+5% +$1.21M 0.02% 747
2018
Q2
$25.1M Sell
1,569,573
-278,038
-15% -$4.11M 0.02% 714
2018
Q1
$23.9M Sell
1,847,611
-27,307
-1% -$340K 0.02% 763
2017
Q4
$23.5M Sell
1,874,918
-54
-0% -$705 0.02% 801
2017
Q3
$24.8M Buy
1,874,972
+270,742
+17% +$3.73M 0.02% 712
2017
Q2
$25.4M Sell
1,604,230
-141,939
-8% -$2.06M 0.02% 689
2017
Q1
$24.9M Sell
1,746,169
-114,594
-6% -$1.57M 0.02% 715
2016
Q4
$23.8M Buy
1,860,763
+92,732
+5% +$1.17M 0.02% 719
2016
Q3
$23.5M Sell
1,768,031
-125,494
-7% -$1.47M 0.02% 738
2016
Q2
$20.7M Buy
1,893,525
+5,589
+0.3% +$54.6K 0.02% 749
2016
Q1
$17.3M Buy
1,887,936
+143,048
+8% +$1.18M 0.02% 788
2015
Q4
$16.9M Buy
1,744,888
+26,347
+2% +$255K 0.02% 867
2015
Q3
$15M Sell
1,718,541
-7,478
-0.4% -$69.8K 0.02% 900
2015
Q2
$17.4M Buy
1,726,019
+1,592,040
+1,188% +$18.5M 0.02% 911
2015
Q1
$1.79M Sell
133,979
-5,103
-4% -$67K ﹤0.01% 2485
2014
Q4
$1.78M Buy
139,082
+59,271
+74% +$678K ﹤0.01% 2638
2014
Q3
$866K Sell
79,811
-704,880
-90% -$8.07M ﹤0.01% 3177
2014
Q2
$10.1M Buy
784,691
+651,150
+488% +$7.08M 0.01% 1396
2014
Q1
$1.38M Sell
133,541
-19,340
-13% -$217K ﹤0.01% 2828
2013
Q4
$1.49M Buy
152,881
+99,576
+187% +$894K ﹤0.01% 2937
2013
Q3
$529K Sell
53,305
-74,631
-58% -$732K ﹤0.01% 3466
2013
Q2
$1.06M Buy
+127,936
New +$1.55M ﹤0.01% 2743

Other funds holding IRWD

Credit Suisse's IRWD Position: Q1 2024 in Review

Credit Suisse reduced its Ironwood Pharmaceuticals (IRWD) stake by 96% in Q1 2024, selling an estimated $65.7M and leaving 197,789 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1959.

Credit Suisse first reported a position in IRWD in Q2 2013 and has held it in 44 quarters since. The position peaked at $64.4M in Q4 2022. 261 funds tracked by Wall St. Rank hold IRWD as of Q1 2024.

  • Credit Suisse held 197,789 shares of Ironwood Pharmaceuticals worth $1.72M as of Q1 2024.
  • Credit Suisse sold 5,414,324 Ironwood Pharmaceuticals shares in Q1 2024, an estimated $65.7M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1959 holding.
  • Credit Suisse first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Ironwood Pharmaceuticals position peaked at $64.4M in Q4 2022.
  • 261 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.